Search Results
Your search for ,aLl matches 18304 pages
Showing 6251 - 6300Making Strides in the Management of Pancreatic Cancer
The Special Conference on Pancreatic Cancer, sponsored by the American Association for Cancer Research (AACR) and held virtually this year, showcased cutting-edge discoveries and promising advances in the understanding and treatment of pancreatic cancer, reported by some of the world’s foremost...
New Study Finds Low Rates of Bone Mineral Density Testing in Men Treated With ADT for Prostate Cancer
A report published by Hu et al in JNCCN—Journal of the National Comprehensive Cancer Network found the rate of bone mineral density testing in people with prostate cancer undergoing androgen-deprivation therapy (ADT) has improved in recent years, but remains low. ADT is considered a cornerstone of...
NeoALTTO Trial: Final Analysis Examines Neoadjuvant Lapatinib/Trastuzumab in HER2-Positive Breast Cancer
Final analysis of results from a randomized clinical trial of lapatinib and trastuzumab given before surgery in patients with early HER2-positive breast cancer has found that women who had a pathologic complete response survived longer without cancer recurrence than patients who did not. This was...
Nab-paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer
In a phase II trial reported in JAMA Oncology, Srikala S. Sridhar, MD, MSc, FRCPC, and colleagues found no difference in progression-free survival with nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer. Study Details In the investigator-initiated...
Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC
In the Spanish phase II NADIM trial reported in The Lancet Oncology, Provencio et al found that the addition of nivolumab to neoadjuvant chemotherapy and the use of adjuvant nivolumab were associated with high 24-month rates of progression-free survival in patients with resectable stage IIIA...
Tell Your Patients About ASCO’s Oncologist-Approved Patient Information Website
ASCO believes that the best cancer care starts with the best cancer information. Its patient education website, Cancer.Net, gives patients and caregivers expertise and resources from ASCO in plain, easy-to-understand language so that they may make informed health-care decisions. Refer your patients ...
Unique Patient Identifiers Could Help Streamline Nation’s Health Information Technology Infrastructure
The Association for Clinical Oncology (ASCO) recently submitted comments to the Office of the National Coordinator for Health Information Technology (ONC) in response to its request for comments on improving patient identification and matching in the nation’s health information technology...
Conquer Cancer Announces 2020 Quality Care Symposium Merit Awards
Conquer Cancer, the ASCO Foundation® is pleased to announce the recipients of its 2020 Quality Care Symposium Merit Awards. These distinguished awards recognize oncology fellows and trainees who are first authors on top-ranking abstracts selected for presentation at the virtual ASCO Quality Care...
Bolder, More Aggressive Steps Needed to Achieve Cancer Care Equity
ASCO called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO),...
Conquer Cancer Offers New Research Grants Targeting Diversity in Research, Underserved Patients
The oncology workforce struggles with adequate representation of racial and ethnic minorities, with only 2.3% of practicing oncologists self-identifying as Black or African American and 5.8% of practicing oncologists self-identifying as Hispanic.1 Conquer Cancer, the ASCO Foundation® is offering a...
Art of Oncology: On the Page and in a Podcast, Personal Reflections From Oncologists Are a Fitting Companion Amid the COVID-19 Pandemic
The well-loved Art of Oncology section of the Journal of Clinical Oncology (JCO) and its pioneering podcast are both resonating as never before, as cancer specialists are prompted into deeper reflections about the poignant moments that give life meaning by the COVID-19 pandemic. JCO’s Art of...
Surgical Oncologist Diane M. Simeone, MD, Strives to Improve Outcomes for Patients With Pancreatic Cancer
Despite decades of research and clinical advances, the diagnosis and treatment of pancreatic cancer remain formidable challenges. Recently, enormous efforts have been made to develop new methods for the early diagnosis and treatment of pancreatic cancer, such as those led by Diane M. Simeone, MD, a ...
Trends to Watch in Early-Onset Cancer Among Young Adults
Although cancer incidence and mortality rates for all cancers combined are considerably lower in younger adults than older adults, a disturbing pattern is beginning to emerge in the development of early-onset cancers, typically diagnosed in older patients, occurring in younger adults. The rising...
Pralsetinib for NSCLC With RET Gene Fusions
On September 4, 2020, pralsetinib (Gavreto) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for treatment of adults with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test.1,2 The FDA simultaneously approved the...
A Leader in Drug Development, Patricia Keegan, MD, Reflects on Making a Difference in Cancer Care
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Patricia Keegan, MD, who served at the U.S. Food and Drug Administration (FDA) for 30 years, most recently as Acting Associate Director of Medical Policy at the Oncology Center for Excellence (OCE)....
Dana-Farber Cancer Institute to Establish Benderson Family Program for Triple-Negative Breast Cancer
Dana-Farber Cancer Institute has received a $5 million gift from the Benderson Family of Sarasota, Florida, that will accelerate research in triple-negative breast cancer (TNBC) and strengthen Dana-Farber’s capabilities for treating this disease. The gift establishes the Benderson Family Program...
How Anxiety, Depression, and Low Social Support Impact the Intensity of Cancer Pain
Pain is one of the most common byproducts of cancer and its treatment. Tumors, surgery, intravenous chemotherapy, radiation therapy, targeted therapy, supportive care therapies (such as bisphosphonates), and diagnostic procedures can all cause pain in patients and may contribute to symptoms of...
Impact of Cytotoxic Chemotherapy Within 5 Weeks of COVID-19 Diagnosis in Patients With Cancer
In a single-institution study reported in the Journal of Clinical Oncology, Justin Jee, MD, PhD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center (MSK), New York, and colleagues found that receipt of cytotoxic chemotherapy within 35 days of COVID-19 diagnosis in patients with...
Eliminating Routine Opioids While Maintaining Pain Control for Women Undergoing Lumpectomy or Excisional Biopsy
Changing from routinely prescribing opioids for patients who were having a lumpectomy or excisional biopsy to instead routinely prescribing nonsteroidal anti-inflammatory drugs [NSAIDs] resulted in a sharply decreased opioid prescription rate with “no difference in the proportion of patients...
Addition of Nelarabine to Standard Therapy Improves Disease-Free Survival in Newly Diagnosed T-Cell ALL
As reported in the Journal of Clinical Oncology by Kimberly P. Dunsmore, MD, of the Virginia Tech Carilion School of Medicine and Carilion Clinic, Roanoke, and colleagues, the phase III Children’s Oncology Group AALL0434 trial has shown that the addition of nelarabine to standard therapy improved...
Expert Point of View: Elizabeth Smyth, MD
The overall survival benefit for PD-L1 CPS ≥ 5 tumors in CheckMate 649 is a game-changer. An oxaliplatin doublet plus chemotherapy should become a standard of care for these patients,” according to Elizabeth Smyth, MD, an oncology consultant at Cambridge University Hospital NHS Foundation Trust in...
Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?
As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...
Immunologist Thirumala-Devi Kanneganti, PhD, Receives NCI Outstanding Investigator Award
Thirumala-Devi Kanneganti, PhD, Vice Chair of the St. Jude Children’s Research Hospital Department of Immunology, has received a National Cancer Institute (NCI) Outstanding Investigator Award to build on her discoveries related to the innate immune system, inflammation, and cell death in health and ...
Total Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Patients with pancreatic adenocarcinoma who underwent total neoadjuvant therapy, consisting of chemotherapy followed by chemoradiation prior to surgery, had improved overall survival compared with those who had single-agent neoadjuvant therapy or surgery first, according to a large cohort study...
Expert Point of View: Johan Vansteenkiste, MD
Formal study discussant Johan Vansteenkiste, MD, of the University Hospitals KU Leuven, Belgium, commented on the ADAURA trial findings: “This is an impressive effect on disease-free survival [with osimertinib] and a very early snapshot of overall survival.” Dr. Vansteenkiste continued: “In the CNS ...
Impact of Adjuvant Osimertinib on CNS Recurrence of NSCLC: ADAURA Trial
Osimertinib significantly prolonged disease-free survival compared with placebo in patients with completely resected stage II to IIIA non–small cell lung cancer (NSCLC), according to the results of the large randomized phase III ADAURA trial presented at the European Society for Medical Oncology...
Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes
The Lung ART trial was designed to demonstrate whether there is any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) stage IIIA N2 (ie, patients with mediastinal nodal involvement) following complete resection and neo...
First-Line Nivolumab Plus Cabozantinib Improves Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma
The combination of nivolumab plus cabozantinib was found to be superior to the former standard, sunitinib, in the first-line treatment of advanced or metastatic renal cell carcinoma, according to the results of the phase III CheckMate 9ER trial reported at the European Society for Medical Oncology...
A Primary Care Physician Explores Barriers to Cancer Prevention and Clinical Trial Accrual
To accelerate progress in the survival rates of people with cancer in the United States and to reduce cancer disparities across the entire spectrum of cancer from diagnosis to survivorship, there needs to be increased access to cancer screening and prevention programs. To shed light on this...
Mobilizing for Greater Equity in Health Care Despite the Challenges of COVID-19
The lockdown phase of the coronavirus (COVID-19) pandemic and continued measures, such as social distancing, while necessary, are disrupting cancer care in ways that will have consequences for months, if not years, to come. Studies are showing that delayed or suspended cancer treatments,...
My Inherited Condition Has Led to a Life and Career I Love
My father died of thymic cancer when I was 14, and that’s when I decided to become an oncologist. Ironically, the first patient I diagnosed with cancer was me. In 2009, during my first week of training in hematology/oncology at the Mayo Clinic, I began having severe abdominal pain, which had...
City of Hope Hires Stephen Gruber, MD, PhD, MPH, to Head Its Center for Precision Medicine
Cancer geneticist Stephen Gruber, MD, PhD, MPH, has joined City of Hope as Director of its newly founded Center for Precision Medicine. He will lead a team of more than 14 researchers who will work across the institution to pioneer personalized cancer prevention and treatment plans. As a medical...
Study Finds Racial Disparities in Management of Colorectal Cancer Spreading to the Liver
Colorectal cancer is more prevalent among Black people, a group with the highest rates of death for an illness that is curable if caught early. “The unfortunate reality is that minorities, especially Black people, have a much lower chance of getting life-saving cancer treatment. Health care works...
Neck Tumor
The text and photographs here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
A Young Oncologist Cares for Patients With Cancer Amid COVID-19 Pandemic
The COVID-19 pandemic changed the face of U.S. health-care services in such rapid fashion that many providers were caught off guard, learning and preparing on the fly. Patients with cancer, given their multiple physical and emotional challenges, were especially vulnerable. To get a sense of the...
Phase III NALA Trial Meets Primary Endpoint in Previously Treated HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Cristina Saura, MD, of Vall d’Hebron University Hospital, Barcelona, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with the irreversible pan-HER tyrosine kinase inhibitor neratinib plus...
City of Hope Scientists Explore Combination Immunotherapy for Solid Tumors
City of Hope scientists have combined two immunotherapies—an oncolytic virus and chimeric antigen receptor (CAR) T-cell therapy—to target solid tumors that are otherwise difficult to treat with CAR T-cell therapy alone, according to a recent study in Science Translational Medicine.1 In preclinical...
Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases
For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), no single regimen is an established standard of care. More than 50% of these patients will develop brain metastasis, and thus far, treatments...
Chemistry of Caring: Timeless Lessons From Oncology Fellowship
As a high school student growing up in St Petersburg, Russia, I was so obsessed with chemistry that I begged my professor for extra problems to complete after school. When I rode the bus home on cold winter evenings, I traced chemical reactions with my finger in the frost on the window. By the...
Managing Breast Cancer in a Pregnant Patient
“One of the most challenging oncologic situations is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Associate Dean, Regulatory Affairs; Director of the Breast Care Center; and Professor of Surgery, Pathology, and Biomedical Engineering at the University of...
High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...
A Leading Light in Cancer Advances, Mary Lasker Used Wealth and Connections to Increase Funding for Medical Research
Born in Watertown, Wisconsin, in 1900, Mary Woodard Lasker was introduced to the ravages of cancer when she was just 3 or 4 years old and went with her mother to visit the family’s laundress, Mrs. Belter, who had just undergone surgery for breast cancer. On the way over to Mrs. Belter’s home, Ms....
HER2-Positive Metastatic Breast Cancer Highlights 2019–2020 Almanac
The past 2 years have seen a dramatic change in the standard of care for patients with HER2-positive metastatic breast cancer whose disease has progressed on trastuzumab. Promising new agents and combinations for later lines of therapy may also challenge current treatment strategies, according to...
Cancer in Older Adults: The History of Geriatric Oncology, 1980–2015
The development of geriatric oncology has been slow but progressive. Thanks to the effort of investigators throughout the world, embattled but undeterred by the objection of a cautious establishment, geriatric oncology has provided a blueprint for the treatment of cancer in the population of...
Astragalus
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on the...
Retrospective Analysis From the BIG 2-98 Trial of Adjuvant Docetaxel-Based Chemotherapy for Early Breast Cancer
A retrospective analysis from the BIG 2-98 trial reported in the Journal of Clinical Oncology by Christine Desmedt, PhD, of the Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Belgium, and colleagues showed poorer disease-free and overall survival with...
Red Flag Presentations of Immunoglobulin Light Chain Amyloidosis in Patients With Multiple Myeloma
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, the authors highlight the most common type of systemic amyloidosis in the United States: immunoglobulin light chain [or amyloid light...
Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, Honored With Nobel Prize in Chemistry 2020
On October 7, 2020, The Royal Swedish Academy of Sciences announced that the Nobel Prize in Chemistry 2020 would be awarded to Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, “for the development of a method for genome editing,” the CRISPR/Cas9 genetic scissors. “There is enormous power...
Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?
Patients receiving care for advanced cancer based on the recommendations of a molecular tumor board were more likely to survive or experience a longer period without disease progression, according to results from a study published by Kato et al in Nature Communications. Razelle Kurzrock, MD,...
Breast Cancer Risk After Benign Breast Disease
Benign breast disease is known to increase the chances of subsequent breast cancer. According to Spanish researchers, the way benign breast disease is detected may be an indication of how likely it is to become cancerous. The findings from the team led by Xavier Castells, MD, PhD, Head of the...
